利伐沙班单药对比联合抗血小板治疗对房颤合并稳定冠心病患者血栓与出血总事件的影响:AFIRE试验事后二次分析
该研究为AFIRE随机临床试验的事后二次分析,纳入2215例房颤合并稳定冠心病患者,比较利伐沙班单药与联合抗血小板治疗对血栓和/或出血总事件的影响。结论提示此类患者可考虑仅用抗凝药的单药治疗。
要点
- 利伐沙班单药较联合抗血小板显著降低血栓和/或出血总事件风险(HR 0.62)。
- 单药组总事件发生率12.2%,联合组19.2%,中位随访24.1个月。
- 出血事件后死亡率高于血栓事件后死亡率,支持简化抗栓治疗。
核心结论
- 在房颤合并稳定冠心病患者中,利伐沙班单药治疗与联合抗血小板治疗相比,血栓和/或出血总事件风险更低。
- 对此类患者应考虑仅使用单一抗凝药的简化抗栓治疗策略。
研究设计与样本
- AFIRE开放标签随机临床试验的事后二次分析,多中心进行,时间为2015年2月23日至2018年7月31日。
- 纳入房颤合并稳定冠心病患者,这些患者既往1年及以上接受过经皮冠状动脉介入治疗或冠状动脉旁路移植术,或血管造影证实冠心病但无需血运重建。
- 改良意向治疗分析共纳入2215例患者,平均(标准差)年龄74(8.2)岁,男性1751例(79.1%)。
主要发现
- 中位随访24.1个月(IQR 17.3-31.5),单药组总事件发生率为12.2%(135/1107),联合治疗组为19.2%(213/1108)。
- 单药组死亡率为3.7%(41/1107),联合治疗组为6.6%(73/1108)。
- 单药治疗是后续事件风险降低的独立相关因素。
- 出血事件后死亡率(单药组75%[6/8],联合组62.1%[18/29])高于血栓事件后死亡率(单药组25%[2/8],联合组37.9%[11/29])。
临床怎么用
- 对于房颤合并稳定冠心病且符合AFIRE入组条件的患者,可考虑利伐沙班单药抗凝治疗,而非联合抗血小板治疗,以降低血栓和出血总事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Appropriate regimens of antithrombotic therapy for patients with atrial fibrillation (AF) and coronary artery disease (CAD) have not yet been established. OBJECTIVE: To compare the total number of thrombotic and/or bleeding events between rivaroxaban monotherapy and combined rivaroxaban and antiplatelet therapy in such patients. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc secondary analysis of the Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease (AFIRE) open-label, randomized clinical trial. This multicenter analysis was conducted from February 23, 2015, to July 31, 2018. Patients with AF and stable CAD who had undergone percutaneous coronary intervention or coronary artery bypass grafting 1 or more years earlier or who had angiographically confirmed CAD not requiring revascularization were enrolled. Data were analyzed from September 1, 2020, to March 26, 2021. INTERVENTIONS: Rivaroxaban monotherapy or combined rivaroxaban and antiplatelet therapy. MAIN OUTCOMES AND MEASURES: The total incidence of thrombotic, bleeding, and fatal events was compared between the groups. Cox regression analyses were used to estimate the risk of subsequent events in the 2 groups, with the status of thrombotic or bleeding events that had occurred by the time of death used as a time-dependent variable. RESULTS: A total of 2215 patients (mean [SD] age, 74 [8.2] years; 1751 men [79.1%]) were included in the modified intention-to-treat analysis. The total event rates for the rivaroxaban monotherapy group (1107 [50.0%]) and the combination-therapy group (1108 [50.0%]) were 12.2% (135 of 1107) and 19.2% (213 of 1108), respectively, during a median follow-up of 24.1 (IQR, 17.3-31.5) months. The mortality rate was 3.7% (41 of 1107) in the monotherapy group and 6.6% (73 of 1108) in the combination-therapy group. Rivaroxaban monotherapy was associated with a lower risk of total events compared with combination therapy (hazard ratio, 0.62; 95% CI, 0.48-0.80; P < .001). Monotherapy was an independent factor associated with a lower risk of subsequent events compared with combination therapy. The mortality risk after a bleeding event (monotherapy, 75% [6 of 8]; combination therapy, 62.1% [18 of 29]) was higher than that after a thrombotic event (monotherapy, 25% [2 of 8]; combination therapy, 37.9% [11 of 29]). CONCLUSIONS AND RELEVANCE: Rivaroxaban monotherapy was associated with lower risks of total thrombotic and/or bleeding events than combination therapy in patients with AF and stable CAD. Tapered antithrombotic therapy with a sole anticoagulant should be considered in these patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02642419.
引用
- Naito R, Miyauchi K, Yasuda S, et al. Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial. JAMA Cardiol. 2022. PMID: 35704345. doi:10.1001/jamacardio.2022.1561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。